TY  - GEN
AU  - Bremer,Edwin
AU  - ten Cate,Bram
AU  - Samplonius,Douwe F
AU  - Mueller,Nicole
AU  - Wajant,Harald
AU  - Stel,Alja J
AU  - Chamuleau,Martine
AU  - van de Loosdrecht,Arjan A
AU  - Stieglmaier,Julia
AU  - Fey,Georg H
AU  - Helfrich,Wijnand
TI  - Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists
SN  - 1538-7445
PY  - 2008///0214
KW  - Animals
KW  - Antibodies, Monoclonal
KW  - administration & dosage
KW  - Antibodies, Monoclonal, Murine-Derived
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Apoptosis
KW  - drug effects
KW  - B-Lymphocytes
KW  - CHO Cells
KW  - Cricetinae
KW  - Cricetulus
KW  - Fas Ligand Protein
KW  - agonists
KW  - Female
KW  - Genetic Therapy
KW  - adverse effects
KW  - Humans
KW  - Leukemia, Lymphocytic, Chronic, B-Cell
KW  - genetics
KW  - Lymphoma, Non-Hodgkin
KW  - Male
KW  - Recombinant Fusion Proteins
KW  - Rituximab
KW  - Signal Transduction
KW  - Single-Chain Antibodies
KW  - Tumor Cells, Cultured
N1  - Publication Type: Comparative Study; Evaluation Study; Journal Article; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1158/0008-5472.CAN-07-5171
ER  -